{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T03:01:08Z","timestamp":1776394868542,"version":"3.51.2"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00210-025-04921-2","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T09:48:10Z","timestamp":1767433690000},"page":"8517-8526","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of bevacizumab combined with anti-epidermal growth factor receptor monoclonal antibody-targeted drugs in patients with metastatic colorectal cancer"],"prefix":"10.1007","volume":"399","author":[{"given":"Zhehui","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"issue":"1","key":"4921_CR2","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/1740774520975120","volume":"18","author":"E Basch","year":"2021","unstructured":"Basch E, Becker C, Rogak LJ, Schrag D, Reeve BB, Spears P, Smith ML, Gounder MM, Mahoney MR, Schwartz GK, Bennett AV, Mendoza TR, Cleeland CS, Sloan JA, Bruner DW, Schwab G, Atkinson TM, Thanarajasingam G, Bertagnolli MM, Dueck AC (2021) Composite grading algorithm for the National Cancer Institute\u2019s patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Clin Trials 18(1):104\u2013114. https:\/\/doi.org\/10.1177\/1740774520975120","journal-title":"Clin Trials"},{"issue":"3","key":"4921_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","volume":"19","author":"AB Benson","year":"2021","unstructured":"Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Farkas L, Garrido-Laguna I, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Johung KL, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Gurski LA (2021) Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19(3):329\u2013359. https:\/\/doi.org\/10.6004\/jnccn.2021.0012","journal-title":"J Natl Compr Canc Netw"},{"key":"4921_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.982983","volume":"12","author":"AM Berz","year":"2022","unstructured":"Berz AM, Dromain C, Vietti-Violi N, Boughdad S, Duran R (2022) Tumor response assessment on imaging following immunotherapy. Front Oncol 12:982983. https:\/\/doi.org\/10.3389\/fonc.2022.982983","journal-title":"Front Oncol"},{"issue":"1","key":"4921_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3233\/TUB-200069","volume":"43","author":"K Bj\u00f6rkman","year":"2021","unstructured":"Bj\u00f6rkman K, Mustonen H, Kaprio T, Kekki H, Pettersson K, Haglund C, B\u00f6ckelman C (2021) CA125: a superior prognostic biomarker for colorectal cancer compared to CEA, CA19-9 or CA242. Tumour Biol 43(1):57\u201370. https:\/\/doi.org\/10.3233\/TUB-200069","journal-title":"Tumour Biol"},{"issue":"1","key":"4921_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S, Arnold D, Normanno N, Ta\u00efeb J, Seligmann J, De Baere T, Osterlund P, Yoshino T, Martinelli E, ESMO Guidelines Committee (2023) Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 34(1):10\u201332. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.003","journal-title":"Ann Oncol"},{"issue":"4","key":"4921_CR7","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(19)30862-9","volume":"21","author":"C Cremolini","year":"2020","unstructured":"Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A, GONO Foundation Investigators (2020) Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 21(4):497\u2013507. https:\/\/doi.org\/10.1016\/S1470-2045(19)30862-9","journal-title":"Lancet Oncol"},{"issue":"5","key":"4921_CR8","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.21037\/jgo-22-797","volume":"13","author":"Q Ding","year":"2022","unstructured":"Ding Q, Sun Y, Zhang J, Yao Y, Huang D, Jiang Y (2022) Utility and specificity of plasma heat shock protein 90 alpha, CEA, and CA199 as the diagnostic test in colorectal cancer liver metastasis. J Gastrointest Oncol 13(5):2497\u20132504. https:\/\/doi.org\/10.21037\/jgo-22-797","journal-title":"J Gastrointest Oncol"},{"key":"4921_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102017","volume":"86","author":"J Garcia","year":"2020","unstructured":"Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, Chinot OL (2020) Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15years of clinical experience and future outlook. Cancer Treat Rev 86:102017. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102017","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"4921_CR10","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","volume":"15","author":"V Heinemann","year":"2014","unstructured":"Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenm\u00fcller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, M\u00fcller S, Link H, Niederle N, Rost A, H\u00f6ffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15(10):1065\u201375. https:\/\/doi.org\/10.1016\/S1470-2045(14)70330-4","journal-title":"Lancet Oncol"},{"key":"4921_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115388","volume":"220","author":"JW Holch","year":"2025","unstructured":"Holch JW, Ohnmacht AJ, Stintzing S, Heinrich K, Weiss L, Probst V, Stahler A, von Fischer Weikersthal L, Decker T, Kiani A, Kaiser F, Heintges T, Kahl C, Kullmann F, Link H, H\u00f6ffkes HG, Moehler M, Modest DP, Menden MP, Heinemann V (2025) FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: refining first-line treatment selection by combining clinical parameters: a post hoc analysis of the randomized open-label phase III trial FIRE-3\/AIO KRK0306. European journal of cancer (Oxford, England\u202f: 1990) 220:115388. https:\/\/doi.org\/10.1016\/j.ejca.2025.115388","journal-title":"European journal of cancer (Oxford, England : 1990)"},{"issue":"6","key":"4921_CR12","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1080\/14737140.2023.2208353","volume":"23","author":"T Krishnan","year":"2023","unstructured":"Krishnan T, Wang F, Karapetis C, Roy A, Price T (2023) Primary site and treatment impact in unresectable metastatic colorectal cancer. Expert Rev Anticancer Ther 23(6):617\u2013623. https:\/\/doi.org\/10.1080\/14737140.2023.2208353","journal-title":"Expert Rev Anticancer Ther"},{"key":"4921_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cancergen.2024.05.002","volume":"286","author":"D Liu","year":"2024","unstructured":"Liu D, Shen M, Liu Z, Chen D, Pan Y, Zhang L, Xu X (2024) SP1-induced circ_0017552 modulates colon cancer cell proliferation and apoptosis via up-regulation of NET1. Cancer Genet 286:1\u201310. https:\/\/doi.org\/10.1016\/j.cancergen.2024.05.002","journal-title":"Cancer Genet"},{"issue":"8","key":"4921_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101142","volume":"4","author":"I Marrocco","year":"2023","unstructured":"Marrocco I, Giri S, Simoni-Nieves A, Gupta N, Rudnitsky A, Haga Y, Romaniello D, Sekar A, Zerbib M, Oren R, Lindzen M, Fard D, Tsutsumi Y, Lauriola M, Tamagnone L, Yarden Y (2023) L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: comparison of osimertinib vs. cetuximab. Cell Rep Med 4(8):101142. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101142","journal-title":"Cell Rep Med"},{"issue":"10","key":"4921_CR15","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1001\/jamaoncol.2021.2915","volume":"7","author":"E Martinelli","year":"2021","unstructured":"Martinelli E, Martini G, Famiglietti V, Troiani T, Napolitano S, Pietrantonio F, Ciardiello D, Terminiello M, Borrelli C, Vitiello PP, De Braud F, Morano F, Avallone A, Normanno N, Nappi A, Maiello E, Latiano T, Falcone A, Cremolini C, Rossini D, Santabarbara G, Pinto C, Santini D, Cardone C, Zanaletti N, Di Liello A, Renato D, Esposito L, Marrone F, Ciardiello F (2021) Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial. JAMA Oncol 7(10):1529\u20131535. https:\/\/doi.org\/10.1001\/jamaoncol.2021.2915","journal-title":"JAMA Oncol"},{"issue":"24","key":"4921_CR16","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.125884","volume":"4","author":"J Mikulak","year":"2019","unstructured":"Mikulak J, Oriolo F, Bruni E, Roberto A, Colombo FS, Villa A, Bosticardo M, Bortolomai I, Lo Presti E, Meraviglia S, Dieli F, Vetrano S, Danese S, Della Bella S, Carvello MM, Sacchi M, Cugini G, Colombo G, Klinger M, Spaggiari P, Roncalli M, Prinz I, Ravens S, di Lorenzo B, Marcenaro E, Silva-Santos B, Spinelli A, Mavilio D (2019) Nkp46-expressing human gut-resident intraepithelial V\u03b41 T cell subpopulation exhibits high antitumor activity against colorectal cancer. JCI Insight 4(24):e125884. https:\/\/doi.org\/10.1172\/jci.insight.125884","journal-title":"JCI Insight"},{"key":"4921_CR17","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.18632\/oncotarget.28281","volume":"13","author":"R Moench","year":"2022","unstructured":"Moench R, Gasser M, Nawalaniec K, Grimmig T, Ajay AK, de Souza LCR, Cao M, Luo Y, Hoegger P, Ribas CM, Ribas-Filho JM, Malafaia O, Lissner R, Hsiao LL, Waaga-Gasser AM (2022) Platelet-derived growth factor (PDGF) cross-signaling via non-corresponding receptors indicates bypassed signaling in colorectal cancer. Oncotarget 13:1140\u20131152. https:\/\/doi.org\/10.18632\/oncotarget.28281","journal-title":"Oncotarget"},{"issue":"2","key":"4921_CR18","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.amjsurg.2016.01.025","volume":"212","author":"Z Moghadamyeghaneh","year":"2016","unstructured":"Moghadamyeghaneh Z, Hanna MH, Hwang G, Mills S, Pigazzi A, Stamos MJ, Carmichael JC (2016) Outcomes of colon resection in patients with metastatic colon cancer. Am J Surg 212(2):264\u2013271. https:\/\/doi.org\/10.1016\/j.amjsurg.2016.01.025","journal-title":"Am J Surg"},{"issue":"5","key":"4921_CR19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.clinthera.2025.01.019","volume":"47","author":"T Morimoto","year":"2025","unstructured":"Morimoto T, Fujito K, Goto R (2025) Cost-effectiveness analysis of SOX plus bevacizumab versus SOX plus cetuximab for first-line treatment of KRAS wild-type metastatic colorectal cancer in Japan. Clin Ther 47(5):347\u2013354. https:\/\/doi.org\/10.1016\/j.clinthera.2025.01.019","journal-title":"Clin Ther"},{"issue":"4","key":"4921_CR20","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.31557\/APJCP.2023.24.4.1125","volume":"24","author":"DA Perwitasari","year":"2023","unstructured":"Perwitasari DA, Purba FD, Candradewi SF, Marwin M, Permata A, UlfaFaza MB, Septiantoro BP, Kaptein AA (2023) Mapping EORTC-QLQ-C30 onto EQ-5D-5L index in indonesian cancer patients. Asian Pac J Cancer Prev 24(4):1125\u20131130. https:\/\/doi.org\/10.31557\/APJCP.2023.24.4.1125","journal-title":"Asian Pac J Cancer Prev"},{"issue":"23","key":"4921_CR22","doi-asserted-by":"publisher","first-page":"4139","DOI":"10.1002\/cncr.32163","volume":"125","author":"S Piawah","year":"2019","unstructured":"Piawah S, Venook AP (2019) Targeted therapy for colorectal cancer metastases: a review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer 125(23):4139\u20134147. https:\/\/doi.org\/10.1002\/cncr.32163","journal-title":"Cancer"},{"issue":"18","key":"4921_CR23","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, Cruz FM, Wyrwicz L, Stroyakovskiy D, P\u00e1pai Z, Poureau PG, Liposits G, Cremolini C, Bondarenko I, Modest DP, Benhadji KA, Amellal N, Leger C, Vidot L, Tabernero J, SUNLIGHT Investigators (2023) Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med 388(18):1657\u20131667. https:\/\/doi.org\/10.1056\/NEJMoa2214963","journal-title":"N Engl J Med"},{"issue":"19","key":"4921_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194743","volume":"15","author":"J Schardey","year":"2023","unstructured":"Schardey J, Lu C, Neumann J, Wirth U, Li Q, Jiang T, Zimmermann P, Andrassy J, Bazhin AV, Werner J, K\u00fchn F (2023) Differential immune infiltration profiles in colitis-associated colorectal cancer versus sporadic colorectal cancer. Cancers (Basel) 15(19):4743. https:\/\/doi.org\/10.3390\/cancers15194743","journal-title":"Cancers (Basel)"},{"issue":"4","key":"4921_CR26","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.tips.2023.01.003","volume":"44","author":"AE Shin","year":"2023","unstructured":"Shin AE, Giancotti FG, Rustgi AK (2023) Metastatic colorectal cancer: mechanisms and emerging therapeutics. Trends Pharmacol Sci 44(4):222\u2013236. https:\/\/doi.org\/10.1016\/j.tips.2023.01.003","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"4921_CR27","doi-asserted-by":"publisher","first-page":"10217","DOI":"10.1038\/s41467-024-54460-2","volume":"15","author":"M Shiozawa","year":"2024","unstructured":"Shiozawa M, Sunakawa Y, Watanabe T, Ota H, Yasui H, Yabuno T, Tei M, Kochi M, Manaka D, Ohori H, Yamaguchi T, Sagawa T, Kotaka M, Kubota Y, Sekikawa T, Nakamura M, Takeuchi M, Ichikawa W, Fujii M, Tsuji A (2024) Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II deeper trial. Nat Commun 15(1):10217. https:\/\/doi.org\/10.1038\/s41467-024-54460-2","journal-title":"Nat Commun"},{"issue":"4","key":"4921_CR28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/JCO.20.02088","volume":"39","author":"J Tabernero","year":"2021","unstructured":"Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Elez E, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S (2021) Encorafenib plus cetuximab as a new standard of care for previously treatedBRAFV600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J Clin Oncol 39(4):273\u2013284. https:\/\/doi.org\/10.1200\/JCO.20.02088","journal-title":"J Clin Oncol"},{"issue":"23","key":"4921_CR29","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1001\/jama.2017.7105","volume":"317","author":"AP Venook","year":"2017","unstructured":"Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O\u2019Neil BH, Atkins JN, Berry S, Polite BN, O\u2019Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB 3rd, Mulkerin DL, Mayer RJ, Blanke C (2017) Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with kras wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA 317(23):2392\u20132401. https:\/\/doi.org\/10.1001\/jama.2017.7105","journal-title":"JAMA"},{"issue":"2","key":"4921_CR30","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/gastro\/goaa032","volume":"9","author":"S Wang","year":"2020","unstructured":"Wang S, Liu Z, Ma YM, Guan X, Jiang Z, Sun P, Liu ER, Zhang YK, Wang HY, Wang XS (2020) Upregulated insulin receptor tyrosine kinase substrate promotes the proliferation of colorectal cancer cells via the bFGF\/AKT signaling pathway. Gastroenterol Rep 9(2):166\u2013175. https:\/\/doi.org\/10.1093\/gastro\/goaa032","journal-title":"Gastroenterol Rep"},{"issue":"15","key":"4921_CR31","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jama.2023.4428","volume":"329","author":"J Watanabe","year":"2023","unstructured":"Watanabe J, Muro K, Shitara K, Yamazaki K, Shiozawa M, Ohori H, Takashima A, Yokota M, Makiyama A, Akazawa N, Ojima H, Yuasa Y, Miwa K, Yasui H, Oki E, Sato T, Naitoh T, Komatsu Y, Kato T, Hihara M, Soeda J, Misumi T, Yamamoto K, Akagi K, Ochiai A, Uetake H, Tsuchihara K, Yoshino T (2023) Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial. JAMA 329(15):1271\u20131282. https:\/\/doi.org\/10.1001\/jama.2023.4428","journal-title":"JAMA"},{"issue":"1","key":"4921_CR32","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2212419","volume":"388","author":"R Yaeger","year":"2023","unstructured":"Yaeger R, Weiss J, Pelster MS, Spira AI, Barve M, Ou SI, Leal TA, Bekaii-Saab TS, Paweletz CP, Heavey GA, Christensen JG, Velastegui K, Kheoh T, Der-Torossian H, Klempner SJ (2023) Adagrasib with or without cetuximab in colorectal cancer with mutatedKRASG12C. N Engl J Med 388(1):44\u201354. https:\/\/doi.org\/10.1056\/NEJMoa2212419","journal-title":"N Engl J Med"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04921-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04921-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04921-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T02:38:51Z","timestamp":1776393531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04921-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4921"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04921-2","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"27 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The study was approved by the local ethics committee of the Fuzhou Taijiang Hospital, all experiments were performed in accordance with relevant guidelines and regulations such as the Declaration of Helsinki and the patients signed the informed consent form and agreed to be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}